IDENTIFYING BIOMARKERS FOR IMMUNOTHERAPY USING SPATIAL BIOLOGY
With
Associate Professor Arutha Kulasinghe
Chair in Spatial Medicine and Principal Research Fellow,
Frazer Institute, University of Queensland, &
Founding Scientific Director,
Queensland Spatial Biology Centre,
Wesley Research Institute,
Queensland, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | October 2026
Associate Professor Arutha Kulasinghe is a Principal Research Fellow at The University of Queensland’s Frazer Institute, where he leads the Clinical-oMx Lab. He holds the inaugural Brazil Family Chair in Spatial Medicine and is the founding Scientific Director of the Queensland Spatial Biology Centre at the Wesley Research Institute. He completed his PhD at Queensland University of Technology.
A/Prof Kulasinghe is a pioneer of spatial biology in the Asia-Pacific region and among the first to apply spatial transcriptomics, proteomics and interactomics there. He combines these technologies in an integrated multi-omics approach to understand the biology that drives disease. His research centres on immuno-oncology in lung, skin, and head and neck cancers, with a particular focus on the tumour microenvironment and on finding biomarkers that predict which patients will respond to immunotherapy. He also develops liquid biopsy approaches for lung and head and neck cancer, and has led tissue-atlas studies of infectious diseases, including COVID-19 and pandemic influenza.
He has authored more than 120 peer-reviewed publications, in journals including Nature Genetics, Nature Communications, The Lancet Microbe and the Journal of Clinical Oncology. His honours include Cure Cancer’s Researcher of the Year (2023), The Australian’s Top Innovators (2024), a Research Australia UNSW Frontiers Award (2026) and InDaily Queensland’s 40 Under 40 (2026). He has also been named on The Courier-Mail’s Queensland Power Lists for technology and medicine (2026). His work is supported by the MRFF, NHMRC, US Department of Defense, Cancer Australia, Cure Cancer, industry, and hospital and philanthropic partners.
- Source: Supplied
- Media Access Credit: Research Australia 2025-26 Health and Medical Research Awards
You Might also like
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Professor Christoph Hagemeyer
RESEARCH IN NANOBIOTECHNOLOGY
@ MONASH UNIVERSITY
VICTORIA, AUSTRALIA -
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
https://orcid.org/0000-0003-3224-7350